(Q34146975)

31 July 2017

title

The rise of a new GABA pharmacology (English)

1 reference

31 July 2017

1 reference

Hanns Möhler

1

1 reference

31 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21035473

17 August 2024

publication date

28 October 2010

1 reference

full work available at URL

31 July 2017

https://api.elsevier.com/content/article/PII:S002839081000290X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

https://api.elsevier.com/content/article/PII:S002839081000290X?httpAccept=text/plain

17 August 2024

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

17 August 2024

1 reference

31 July 2017

volume

60

1 reference

31 July 2017

issue

7-8

1 reference

31 July 2017

page(s)

1042-1049

1 reference

Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors

31 July 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.

17 August 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.

17 August 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.

17 August 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes

17 August 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Imidazenil prevention of alprazolam-induced acquisition deficit in patas monkeys is devoid of tolerance

17 August 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors

17 August 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Neurosteroids: endogenous regulators of the GABA(A) receptor

17 August 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Neurosteroids shift partial agonist activation of GABA(A) receptor channels from low- to high-efficacy gating patterns.

17 August 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Interaction of Convulsive Ligands with Benzodiazepine Receptors

17 August 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Diazepam-binding inhibitor (DBI)-processing products, acting at the mitochondrial DBI receptor, mediate adrenocorticotropic hormone-induced steroidogenesis in rat adrenal gland

17 August 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.

17 August 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia

17 August 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor.

17 August 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Molecular Mechanisms in the Receptor Action of Benzodiazepines

17 August 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Diazepam binding inhibitor (DBI): a peptide with multiple biological actions

17 August 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Molecular Mechanisms Mediating the Action of Diazepam on GABA Receptors

17 August 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Resolving differences in GABAA receptor mutant mouse studies

17 August 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors

17 August 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.

17 August 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Antipsychotic effects of bretazenil, a partial benzodiazepine agonist in acute schizophrenia--a study group report.

17 August 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines.

17 August 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Properties of γ-aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions

17 August 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies

17 August 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling

17 August 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic

17 August 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits

17 August 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus?

17 August 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Cloning and expression of cDNA for human diazepam binding inhibitor, a natural ligand of an allosteric regulatory site of the gamma-aminobutyric acid type A receptor

17 August 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.

17 August 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study

17 August 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.

17 August 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Novel anxiolytics that act as partial agonists at benzodiazepine receptors

17 August 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Cell type- and synapse-specific variability in synaptic GABAA receptor occupancy

17 August 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Selective antagonists of benzodiazepines

17 August 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations

17 August 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Reversal of pathological pain through specific spinal GABAA receptor subtypes.

17 August 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice

17 August 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Sleep EEG changes after zolpidem in mice

17 August 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABA(A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic

17 August 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Molecular and neuronal substrate for the selective attenuation of anxiety.

17 August 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor

17 August 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Cortical inhibitory neurons and schizophrenia

17 August 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia

17 August 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator.

17 August 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Benzodiazepine receptor: demonstration in the central nervous system

17 August 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Benzodiazepine receptor protein identified and visualized in brain tissue by a photoaffinity label

17 August 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

A new benzodiazepine pharmacology.

17 August 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Role of GABAA receptors in cognition

17 August 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.

17 August 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Pain mechanisms: a new theory

17 August 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy

17 August 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Bridging the cleft at GABA synapses in the brain

17 August 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflamm

17 August 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Some properties of 3H-diazepam displacing activity from human urine

17 August 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist

17 August 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update

17 August 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Diazepam Binding Inhibitor and Its Processing Products Stimulate Mitochondrial Steroid Biosynthesis via an Interaction with Mitochondrial Benzodiazepine Receptors*

17 August 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

The effect of diazepam on spinal cord activities: possible sites and mechanisms of action.

17 August 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone

17 August 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma-aminobutyric acid type A receptor

17 August 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Molecular and neuronal substrates for general anaesthetics

17 August 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABA-based therapeutic approaches: GABAA receptor subtype functions

17 August 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.

17 August 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABA(A) receptor subtypes: dissecting their pharmacological functions

17 August 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects

17 August 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats

17 August 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Purified benzodiazepine receptor retains modulation by GABA

17 August 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

A GABA/benzodiazepine receptor complex from bovine brain: purification, reconstitution and immunological characterization

17 August 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Co-localization of GABA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies

17 August 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Neural synchrony indexes disordered perception and cognition in schizophrenia

17 August 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABA(A) receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits.

17 August 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Benzodiazepine receptors in rat brain

17 August 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity

17 August 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results

17 August 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Diazepam and presynaptic inhibition

17 August 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABAergic modulation of benzodiazepine binding site sensitivity

17 August 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist

17 August 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Ethanol enhances alpha 4 beta 3 delta and alpha 6 beta 3 delta gamma-aminobutyric acid type A receptors at low concentrations known to affect humans

17 August 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

The GABAA receptor gene family: new opportunities for drug development

17 August 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear

17 August 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction

17 August 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Strychnine binding associated with glycine receptors of the central nervous system

17 August 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

Loss of glycinergic and GABAergic inhibition in chronic pain--contributions of inflammation and microglia

17 August 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

GABAergic analgesia: new insights from mutant mice and subtype-selective agonists

17 August 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2010.10.020

17 August 2024

Identifiers

1 reference

31 July 2017

1 reference